Zadaxin

Zadaxin®

Thymosin alpha 1, see there.
References in periodicals archive ?
Its lead product Zadaxin (thymalfasin), marketed since 1996, has been approved in over 30 countries for indications including hepatitis B, hepatitis C, and some types of cancers, as well as an immune system enhancer.
The company's proprietary lead product, Zadaxin (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B, hepatitis C, and certain cancers, and as an immune system enhancer, according to the local regulatory approvals.
The company's ZADAXIN (thymalfasin) is approved in more than 30 countries for use in hepatitis B and C, as a vaccine adjuvant and to treat certain cancers.
SciClone Pharmaceuticals Inc (Foster City CA) posted a quarterly profit that beat market estimates, driven by strong sales of its hepatitis B treatment Zadaxin in China and lower research and development expenses.
SciClone's ZADAXIN is currently being evaluated in several clinical trials, including two phase 3 hepatitis C clinical trials in the U.
SciClone's Zadaxin (Thymosin alfa-1; thymalfasin) is a synthetic peptide, derived from human thymus gland extracts, that modulates immune responses.
The clinical trial will compare the triple combination therapy of Zadaxin, peginterferon alfa-2a and ribavirin to placebo, peginterferon alfa-2a and rebavirin to evaluate the benefit of adding Zadaxin to current therapy for hepatitis C patients who have failed to respond to previous treatment.
Both ZADAXIN and SCV-07 promote differentiation of T cells into the T helper 1 (Th1) subset.
SciClone Pharmaceuticals (San Mateo, CA; 650-358-3437) announced that the United States Patent and Trademark Office has issued a Notice of Allowance for use of the company's lead drug, ZADAXIN plus lamivudine and famciclovir for the treatment of hepatitis B.
Its principal product is ZADAXIN for the treatment of hepatitis B and hepatitis C viruses and certain cancers, as well as for use as a vaccine adjuvant or as a chemotherapy adjuvant for cancer patients with weakened immune systems.
SciClone's proprietary lead product, Zadaxin (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B, hepatitis C, and certain cancers, and as an immune system enhancer, according to the local regulatory approvals.
reported today additional topline results from a clinical study evaluating the potential of ZADAXIN (thymalfasin) to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vaccine, Focetria from Novartis (VTX: NOVN).